| Page 524 | Kisaco Research
 

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts
 

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts
 

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts
 

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts

Aaron Dembroski

Global Wellness Director
Hilton Hotels & Resorts
Interview with Chris Payne, CEO, Jane Iredale
 

Ram Davaloor

Founder and COO
Claimshark

Ram Davaloor

Founder and COO
Claimshark

Ram Davaloor

Founder and COO
Claimshark
 

Chandra Kuti

VP, Government Solutions Operations
CoventBridge Group

Chandra Kuti

VP, Government Solutions Operations
CoventBridge Group

Chandra Kuti

VP, Government Solutions Operations
CoventBridge Group
 

Celine Halioua

Founder & CEO
Loyal

Celine Halioua is the Founder and CEO of Loyal, a clinical-stage animal health company
developing the first longevity drugs for dogs. Since founding Loyal in 2019, she has raised over $150M and has led the company through several historic regulatory milestones, including earning what is believed to be the first- and second-ever acceptances from the FDA that a drugcould be effectively developed for lifespan extension.

Celine Halioua

Founder & CEO
Loyal

Celine Halioua

Founder & CEO
Loyal

Celine Halioua is the Founder and CEO of Loyal, a clinical-stage animal health company
developing the first longevity drugs for dogs. Since founding Loyal in 2019, she has raised over $150M and has led the company through several historic regulatory milestones, including earning what is believed to be the first- and second-ever acceptances from the FDA that a drugcould be effectively developed for lifespan extension.


Prior to Loyal, Celine was Chief of Staff at the Longevity Fund and pursued a DPhil in the
economics of healthcare at Oxford University. She holds a B.S. in neuroscience from the
University of Texas at Austin.